drugset

drugset / Trial / NCT06824454

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

NCT06824454 ↗

Phase 2 Recruiting 90 enrolled Stanford University

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Timeline

Start: 2025-05-15
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dipyridamole	Other / unclassified	75 mg	—

Indications